Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E2100||ECOG||A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-0617||RTOG||A Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GU001||NRG||Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0502||SWOG||A Phase III Randomized Study of Imatinib; with or without Bevacizumab (NSC-704865); in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors NCT #00324987||Adult CIRB - Late Phase Emphasis||Completed|
|GOG-0277||GOG||A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NCS# 123127) versus Observation for Uterus-Limited; High Grade Uterine Leiomyosarcoma||Adult CIRB - Late Phase Emphasis||Completed|
|A041501||Alliance||A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1922||SWOG||Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI In Refractory Small Bowel Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-C-11||NSABP||A Phase III Study Evaluating the Role of Perioperative Chemotherapy in Patients with Potentially Resectable Hepatic Colorectal Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|E6201||ECOG||A Phase III; Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin (NSC 266046) versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-minute infusion] in Pancreatic Carcinoma||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-50303||CALGB||Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas||Adult CIRB - Late Phase Emphasis||Available to Open|